53,101 Shares in MiMedx Group, Inc. (NASDAQ:MDXG) Purchased by OneDigital Investment Advisors LLC

OneDigital Investment Advisors LLC acquired a new stake in MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 53,101 shares of the company's stock, valued at approximately $511,000.

A number of other institutional investors have also recently modified their holdings of the stock. Invesco Ltd. boosted its holdings in shares of MiMedx Group by 2.2% in the 4th quarter. Invesco Ltd. now owns 56,565 shares of the company's stock valued at $544,000 after purchasing an additional 1,226 shares in the last quarter. Tower Research Capital LLC TRC grew its position in MiMedx Group by 77.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,501 shares of the company's stock valued at $63,000 after acquiring an additional 2,837 shares during the last quarter. IMG Wealth Management Inc. acquired a new position in MiMedx Group during the fourth quarter worth about $28,000. SkyView Investment Advisors LLC lifted its holdings in shares of MiMedx Group by 30.0% in the third quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the company's stock worth $77,000 after acquiring an additional 3,000 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its stake in shares of MiMedx Group by 6.3% in the 3rd quarter. Principal Financial Group Inc. now owns 55,495 shares of the company's stock valued at $328,000 after purchasing an additional 3,292 shares in the last quarter. 79.15% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, CAO William Frank Iv Hulse sold 81,446 shares of the business's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $7.80, for a total value of $635,278.80. Following the transaction, the chief accounting officer now owns 494,774 shares in the company, valued at approximately $3,859,237.20. The trade was a 14.13 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Kimberly Maersk-Moller sold 4,106 shares of the stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $7.89, for a total transaction of $32,396.34. Following the sale, the insider now owns 310,836 shares of the company's stock, valued at approximately $2,452,496.04. This trade represents a 1.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 144,018 shares of company stock valued at $1,130,312 in the last three months. Insiders own 1.30% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. Cantor Fitzgerald reiterated an "overweight" rating and set a $13.00 price objective on shares of MiMedx Group in a research report on Thursday, February 27th. StockNews.com upgraded MiMedx Group from a "buy" rating to a "strong-buy" rating in a research note on Thursday.

MiMedx Group Stock Performance

Shares of MiMedx Group stock remained flat at $6.32 on Friday. The stock had a trading volume of 900,613 shares, compared to its average volume of 677,756. The company has a fifty day moving average of $7.40 and a 200 day moving average of $8.09. The stock has a market capitalization of $931.35 million, a price-to-earnings ratio of 11.49 and a beta of 1.74. MiMedx Group, Inc. has a one year low of $5.47 and a one year high of $10.14. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The company reported $0.06 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.06. The firm had revenue of $88.21 million during the quarter, compared to analysts' expectations of $86.32 million. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. Equities analysts expect that MiMedx Group, Inc. will post 0.3 earnings per share for the current year.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.